Company invites individual and institutional investors to attend interactive real-time virtual VirtualInvestorConferences.com
SAN RAMON, Calif., Nov. 22, 2016 /CNW/ --Galena Biopharma Inc. (NASDAQ: GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will present live at VirtualInvestorConferences.com on December 1, 2016.
DATE: Thursday, December 1, 2016
TIME: [10:45 a.m. PT / 1:45 p.m. ET]
This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the association's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.
It is recommended that investors pre-register and run the online system check to save time and receive event updates.
Learn more about the event at www.VirtualInvestorConferences.com.
About Galena Biopharma Inc.
Galena Biopharma Inc. is a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs. Galena's pipeline consists of multiple mid-to-late-stage clinical assets led by our hematology asset, GALE-401, and our novel cancer immunotherapy programs including NeuVax™ (nelipepimut-S), and GALE-301/GALE-302. For more information, please visit our website at https://galenabiopharma.com/
Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.
SOURCE Galena Biopharma Inc.
For further information: Galena Biopharma, Inc., Remy Bernarda, SVP, Investor Relations & Corporate Communications, (925) 498-7709, email@example.com; VirtualInvestorConferences.com, Bradley H. Smith, Director of Marketing, IR and Compliance Services, PR Newswire, +1.201.947.7157, firstname.lastname@example.org, https://galenabiopharma.com